Combining Systemic Therapies for Autoimmune Blistering Diseases

Conclusions

• The presentation concludes that systemic therapy for autoimmune blistering diseases should be individualized based on disease severity, comorbidities, risk factors, and patient goals of care.
• It suggests using the least immunosuppressive effective regimen when possible, while carefully monitoring patients who require multi-drug combinations.
• Rituximab appears highly effective and durable for pemphigus, with better remission and steroid-sparing outcomes than prednisone alone or mycophenolate in the studies discussed.
• Dupilumab appears particularly promising for bullous pemphigoid, showing strong disease control, pruritus reduction, lower relapse rates, and potentially better safety than rituximab in the evidence reviewed.
• IVIG can be a useful adjunct or bridge therapy, especially to help accelerate steroid tapering while waiting for slower steroid-sparing agents to take effect.
• When disease remains recalcitrant despite treatment, clinicians should investigate for underlying triggers or paraneoplastic disease using history, imaging, endoscopy, and appropriate laboratory work-up.
• The case example illustrates that difficult bullous pemphigoid may require repeated therapy adjustment and combination treatment over months before remission is achieved.
• The overall message is that combining therapies can be effective, but it should be done thoughtfully to avoid unnecessary dual immunosuppression and to support safe tapering once control is reached.